Table 1.
Baseline demographic and clinical characteristics of adults 18–64 years old with OUD who initiated buprenorphine treatment between 2013–2015 (N=17,329)
| N | % | |
|---|---|---|
| Demographics | ||
| Sex | ||
| Female | 6,198 | 35.8 |
| Male | 11,131 | 64.2 |
| Age | ||
| 18–24 | 2,339 | 13.5 |
| 25–34 | 8,466 | 48.9 |
| 35–44 | 4,165 | 24.0 |
| 45–54 | 1,722 | 9.9 |
| 55–64 | 637 | 3.7 |
| Race/ethnicity | ||
| White | 14,649 | 84.5 |
| Black | 836 | 4.8 |
| Hispanic | 177 | 1.0 |
| Other | 1,667 | 9.6 |
| Insurance | ||
| FFS | 3,868 | 22.3 |
| Capitation | 13,461 | 77.7 |
| Comorbidities | ||
| Mental Health | ||
| Depression | 4,580 | 26.4 |
| Anxiety | 5,682 | 32.8 |
| PTSD | 621 | 3.6 |
| Bipolar Disorder | 2,319 | 13.4 |
| Schizophrenia | 359 | 2.1 |
| Substance Use | ||
| Alcohol | 1,648 | 9.5 |
| Non-opioid drugs | 7,624 | 44.0 |
| Medical | ||
| Pain | 8,470 | 48.9 |
| Hepatitis C | 2,366 | 13.7 |
| Health Services | ||
| Overdose treatment | ||
| Non-opioid drugs | 857 | 4.9 |
| Opioids | 590 | 3.4 |
| Inpatient | 4,379 | 25.3 |
| Emergency | 2,578 | 14.9 |
| Outpatient | ||
| Therapy | 8,314 | 48.0 |
| Medication management | 1,708 | 9.9 |
| Prescription drugs | ||
| Psychotropic drugs | 10,018 | 57.8 |
| Antidepressants | 7,577 | 43.7 |
| Antipsychotics | 2,535 | 14.6 |
| Mood stabilizers | 4,222 | 24.4 |
| Benzodiazepines | 4,299 | 24.8 |
| Stimulants | 792 | 4.6 |
| Opioids | 9,135 | 52.7 |
| Buprenorphine | ||
| Initial dose >4 MG | 2,155 | 12.4 |
| Initial dose ≤4 MG | 15,174 | 87.6 |
Source: Authors’ analysis of MarketScan Medicaid claims, 2013–2015